Phio Pharmaceuticals Corp. Common Stock
Symbol: PHIO (NASDAQ)
2.63
▲ (4.78%) 0.120
Company Description:
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Key Stats
- Today's Open: $3.02
- Today's High: $3.947
- Today's Low: $2.48
- Today's Volume: 49.54M
- Yesterday Close: $2.51
- Yesterday High: $2.58
- Yesterday Low: $2.48
- Yesterday Volume: 74.09K
- Last Min Volume: 0
- Last Min High: $2.63
- Last Min Low: $2.63
- Last Min VWAP: $0
Company Profile
- Name: Phio Pharmaceuticals Corp. Common Stock
- Website: https://www.phiopharma.com
- Listed Date: 2012-05-10
- Location: MARLBOROUGH, MA
- Market Status: Active
- CIK Number: 0001533040
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $13.15M
- Round Lot: 100
- Outstanding Shares: 4.80M
- Asset Type: CS
RECENT FILINGS FOR PHIO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-25 | 8-K | View |
| 2025-07-07 | 8-K | View |
| 2025-06-26 | 8-K | View |
| 2025-06-18 | 3 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-11 | 4 | View |
| 2025-06-11 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-05-23 | 4 | View |
| 2025-05-21 | 4 | View |
| 2025-05-15 | 10-Q | View |
| 2025-05-15 | 8-K | View |
| 2025-05-07 | 8-K | View |
| 2025-04-22 | 8-K | View |
| 2025-04-09 | 8-K | View |
| 2025-03-31 | 10-K | View |
| 2025-03-31 | 8-K | View |
| 2025-03-04 | 3 | View |
| 2025-02-20 | 8-K | View |
| 2025-02-07 | SCHEDULE 13G/A | View |
Latest News on PHIO